Amiodarone
Antiarrhythmics, Class Iii
- Drug class
- Antiarrhythmics, Class Iii
- Availability
- Prescription only
- Routes
- Oral, Intravenous
- Markets covered
- 3
- Products on record
- 35
Overview
Plain-language summary, compiled from the cited regulatory records
Amiodarone is an antiarrhythmic medication belonging to Class III [1]. It is approved for initiating treatment and preventing recurrent ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients who have not responded to other therapies [1]. Amiodarone injection may also be used for patients with VT/VF who require treatment but cannot take oral medication [1]. Patients may transition to oral amiodarone during or after treatment with the injectable form [1].
This medication is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 27 | May 29, 2026 |
| CA Canada | Health Canada | 5 | June 1, 2026 |
| US United States | FDA | 3 | April 20, 2026 |
GBUnited Kingdom· MHRA
27 products
Uses
g. as a manifestation of Wolff-Parkinson-White syndrome - life-threatening ventricular arrhythmias, including persistent or non-persistent ventricular tachycardia or episodes of ventricular fibrillation Amiodarone Hydrochloride 20 mg/ml solution for infusion can be used where a rapid response is required or where oral administration is not possible.
Amiodarone hydrochloride may be used prior to DC cardioversion.
How to take
CACanada· Health Canada
5 products
Uses
AND CLINICAL USE ................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................
4 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS .......................................................................................................................
15 DRUG INTERACTIONS ....................................................................................................................... 18 DOSAGE AND ADMINISTRATION ...................................................................................................
22 OVERDOSAGE ..................................................................................................................................... 26 ACTION AND CLINICAL PHARMACOLOGY..................................................................................
USUnited States· FDA
3 products
Uses
1 INDICATIONS AND USAGE Amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy.
Amiodarone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see Dosage and Administration (2) ] .
Use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary. Amiodarone hydrochloride injection is an antiarrhythmic agent indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy.
Drug interactions
Known interactions involving Amiodarone. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL015020113 · revised June 16, 2025
- [2]Health Canada (DPD) · 02249502 · revised March 22, 2025
- [3]FDA DailyMed · 0a28ae25-7cc4-4a… · revised January 16, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.